NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology
NKGEN BIOTECH INC (NKGN)
Company Research
Source: GlobeNewswire
SANTA ANA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the XXVII World Congress of Neurology (“WCN 2025”) taking place in Seoul, South Korea, October 12-15, 2025. WCN 2025 is a premier global forum that brings together leading neurologists, researchers, and healthcare professionals to exchange knowledge, foster collaboration, and explore breakthrough innovations in neurological science. At this year’s congress in Seoul, South Korea, NKGen Biotech will present the scientific rationale and latest clinical findings for troculeucel, its investigational autologous, enhanced NK cell therapy for Alzheimer’s disease. This presentation reflects NKGen’s continued com
Show less
Read more
Impact Snapshot
Event Time:
NKGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKGN alerts
High impacting NKGEN BIOTECH INC news events
Weekly update
A roundup of the hottest topics
NKGN
News
- NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.GlobeNewswire
- NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market [Yahoo! Finance]Yahoo! Finance
- NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert MarketGlobeNewswire
- NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy ForumGlobeNewswire
- NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets [Yahoo! Finance]Yahoo! Finance
NKGN
Sec Filings
- 10/8/25 - Form 10-K
- 9/24/25 - Form 8-K
- 9/9/25 - Form 8-K
- NKGN's page on the SEC website